---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-054465"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:42:04.933460+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU

## Summary
- 11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.
- Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.
- Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.
- No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.
- Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data.

## SEC filing metadata
- accession: 0001213900-25-054465
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/0001213900-25-054465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/ea0245793-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-054465
- JSON: https://secwatch.observer/filing/0001213900-25-054465.json
- Plain text: https://secwatch.observer/filing/0001213900-25-054465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.